AI Engines For more Details: Perplexity Kagi Labs You
Anti-inflammatory Effects: Mometasone furoate exerts potent anti-inflammatory effects by inhibiting the production of inflammatory mediators and reducing immune responses associated with skin inflammation and allergic reactions. It helps alleviate symptoms such as redness, itching, swelling, and discomfort associated with inflammatory skin conditions.
Skin Disorders: Mometasone furoate is commonly used to treat a wide range of skin disorders, including atopic dermatitis (eczema), contact dermatitis, seborrheic dermatitis, psoriasis, and allergic reactions. It helps relieve symptoms and improve the appearance of the skin affected by these conditions.
Topical Application: Mometasone furoate is typically applied topically to the affected area of the skin in the form of creams, ointments, or lotions. It is absorbed into the skin and exerts its therapeutic effects locally, minimizing systemic side effects associated with oral corticosteroids.
Nasal Allergies: Mometasone furoate is also available as a nasal spray and is used in the treatment of allergic rhinitis (hay fever) and nasal polyps. It helps reduce nasal congestion, sneezing, itching, and runny nose associated with allergic reactions.
Safety and Side Effects: When used as directed, mometasone furoate is generally safe and well-tolerated. However, long-term or excessive use of topical corticosteroids may lead to side effects such as skin thinning, skin discoloration, acne, stretch marks, and increased susceptibility to skin infections. Nasal formulations may cause mild side effects such as nasal irritation, dryness, or nosebleeds.
Pregnancy and Breastfeeding: The safety of mometasone furoate during pregnancy and breastfeeding has not been fully established. Pregnant or breastfeeding women should consult with their healthcare providers before using mometasone furoate to weigh the potential risks and benefits.
Systemic Absorption: Although mometasone furoate is primarily used topically, some absorption into the bloodstream may occur, particularly with prolonged or extensive use, or when applied to thin or sensitive areas of the skin. Systemic absorption may increase the risk of systemic side effects associated with corticosteroid use.
Precautions: Mometasone furoate should be used with caution in patients with certain medical conditions such as diabetes, immunosuppression, or compromised skin barrier function. It should not be applied to infected or open wounds unless directed by a healthcare provider.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Parabacteroides distasonis | Reduces |
| species | Veillonella atypica | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Parolsenella | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 0 | 1 | Veillonella rodentium | species | Decreases |
| 0 | 1 | Parolsenella catena | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 0 | 1 | Streptococcus sp. FDAARGOS_192 | species | Decreases |
| 0 | 1 | Veillonella dispar | species | Decreases |
| 0 | 1 | Veillonella sp. S12025-13 | species | Decreases |
| 0 | 1 | Veillonella nakazawae | species | Decreases |
| 0 | 1 | Veillonella rogosae | species | Decreases |
| 0 | 1 | Parolsenella massiliensis | species | Decreases |
| 0 | 1 | Collinsella stercoris | species | Decreases |
| 0 | 1 | Veillonella atypica | species | Decreases |
| 0 | 1 | Parafannyhessea umbonata | species | Decreases |
| 0 | 1 | Streptococcus vestibularis | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.7 | 0 | 0 |
| Age-Related Macular Degeneration and Glaucoma | 0.2 | -0.2 | |
| Allergic Rhinitis (Hay Fever) | 0.4 | 0.1 | 3 |
| Allergies | 1.7 | 1 | 0.7 |
| Allergy to milk products | 0.8 | 0.2 | 3 |
| Alopecia (Hair Loss) | 1.1 | 1.1 | |
| Alzheimer's disease | 1 | 1 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0 | 0.3 | 0 |
| Ankylosing spondylitis | 1.7 | 0.3 | 4.67 |
| Anorexia Nervosa | 0.7 | 0.5 | 0.4 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
| Asthma | 0.9 | 0.6 | 0.5 |
| Atherosclerosis | 0.8 | 0 | 0 |
| Atrial fibrillation | 1.2 | 0.2 | 5 |
| Autism | 1.7 | 1.9 | -0.12 |
| Autoimmune Disease | 0.1 | 0 | 0 |
| Barrett esophagus cancer | 0.5 | 0.1 | 4 |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 0.6 | 0.9 | -0.5 |
| Brain Trauma | 0.6 | 0.3 | 1 |
| Cancer (General) | 0.5 | 0 | 0 |
| Carcinoma | 1.1 | 1 | 0.1 |
| Celiac Disease | 0.6 | 1 | -0.67 |
| Cerebral Palsy | 0.7 | 0.3 | 1.33 |
| Chronic Fatigue Syndrome | 1.6 | 2 | -0.25 |
| Chronic Kidney Disease | 1.2 | 0.5 | 1.4 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 0.7 | 0.43 |
| Chronic Urticaria (Hives) | 0.7 | 0.7 | |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.4 | 0 |
| Cognitive Function | 1.1 | 0.2 | 4.5 |
| Colorectal Cancer | 1 | 0.5 | 1 |
| Constipation | 0.3 | 0.3 | |
| Coronary artery disease | 0.9 | 0.5 | 0.8 |
| COVID-19 | 2.1 | 2.1 | 0 |
| Crohn's Disease | 2.3 | 1 | 1.3 |
| deep vein thrombosis | 0 | 0.4 | 0 |
| Denture Wearers Oral Shifts | 1 | 1 | |
| Depression | 1.8 | 2.8 | -0.56 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.7 | 0.4 | 0.75 |
| Endometriosis | 0.4 | 0.9 | -1.25 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 0.6 | 0.5 | 0.2 |
| erectile dysfunction | 0 | 0 | |
| Fibromyalgia | 0.6 | 0.1 | 5 |
| Functional constipation / chronic idiopathic constipation | 0.7 | 0.6 | 0.17 |
| gallstone disease (gsd) | 1.1 | 1.1 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.4 | 0.25 |
| Generalized anxiety disorder | 0.2 | 0.2 | 0 |
| giant cell arteritis | 0 | 0 | |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.4 | 0.1 | 3 |
| Graves' disease | 1.5 | 1.4 | 0.07 |
| Gulf War Syndrome | 0.2 | 0.2 | |
| Halitosis | 0.6 | 0.1 | 5 |
| Hashimoto's thyroiditis | 0.8 | 0.8 | |
| Heart Failure | 0.7 | 0.3 | 1.33 |
| hemorrhagic stroke | 0.2 | 0.2 | |
| Hidradenitis Suppurativa | 0.1 | 0.5 | -4 |
| High Histamine/low DAO | 0.1 | 0.3 | -2 |
| hypercholesterolemia (High Cholesterol) | 0 | 0 | |
| hyperglycemia | 0.9 | 0.2 | 3.5 |
| Hyperlipidemia (High Blood Fats) | 0.4 | 0.4 | 0 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 1.4 | 0.5 | 1.8 |
| Hypothyroidism | 0 | 0 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.7 | 1.1 | -0.57 |
| Inflammatory Bowel Disease | 2 | 2.9 | -0.45 |
| Insomnia | 0.9 | 0.9 | 0 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.5 | 0.5 | 0 |
| Irritable Bowel Syndrome | 2.2 | 1.7 | 0.29 |
| ischemic stroke | 1.2 | 1.2 | |
| Liver Cirrhosis | 2.1 | 1 | 1.1 |
| Long COVID | 1.4 | 2.3 | -0.64 |
| Low bone mineral density | 0 | 0 | |
| Lung Cancer | 0.3 | -0.3 | |
| Mast Cell Issues / mastitis | 0.1 | 0.4 | -3 |
| ME/CFS with IBS | 0.2 | 0.1 | 1 |
| ME/CFS without IBS | 0.2 | 0.6 | -2 |
| membranous nephropathy | 0.1 | 0.1 | |
| Menopause | 0.4 | 0.4 | |
| Metabolic Syndrome | 1.8 | 1.2 | 0.5 |
| Mood Disorders | 2.6 | 2.7 | -0.04 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.9 | |
| Multiple Sclerosis | 1.6 | 1.4 | 0.14 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| myasthenia gravis | 0.1 | 0 | 0 |
| neuropathic pain | 0.2 | -0.2 | |
| Neuropathy (all types) | 0.1 | 0.2 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 0.4 | 1.25 |
| NonCeliac Gluten Sensitivity | 0.4 | 0.4 | |
| Obesity | 2 | 1.5 | 0.33 |
| obsessive-compulsive disorder | 1.5 | 0.2 | 6.5 |
| Osteoarthritis | 0.2 | 0.4 | -1 |
| Osteoporosis | 0.8 | 0.1 | 7 |
| pancreatic cancer | 0.1 | 0.1 | 0 |
| Parkinson's Disease | 2.4 | 1 | 1.4 |
| Polycystic ovary syndrome | 2.3 | 1.1 | 1.09 |
| Postural orthostatic tachycardia syndrome | 0 | 0 | 0 |
| Premenstrual dysphoric disorder | 0.4 | 0.2 | 1 |
| primary biliary cholangitis | 0.6 | 0.6 | 0 |
| Primary sclerosing cholangitis | 1.7 | 1.2 | 0.42 |
| Psoriasis | 1.6 | 0.9 | 0.78 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.4 | 1 | 1.4 |
| Rosacea | 0.3 | 0 | 0 |
| Schizophrenia | 2.4 | 1.1 | 1.18 |
| scoliosis | 0 | 0.3 | 0 |
| Sjögren syndrome | 1.6 | 0.2 | 7 |
| Sleep Apnea | 0.4 | 0 | 0 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.8 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.7 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.7 | -1.33 |
| Systemic Lupus Erythematosus | 0.9 | 0.3 | 2 |
| Tic Disorder | 0.4 | 0.4 | 0 |
| Tourette syndrome | 0.1 | 0.1 | |
| Type 1 Diabetes | 1 | 0.5 | 1 |
| Type 2 Diabetes | 1.8 | 1.2 | 0.5 |
| Ulcerative colitis | 0.9 | 0.6 | 0.5 |
| Unhealthy Ageing | 0.7 | 0.3 | 1.33 |
| Vitiligo | 0.7 | 0.4 | 0.75 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
